

MAS/sJIA Working Party

Chair: Claudia Bracaglia (claudia.bracaglia@opbg.net)

Secretary: Francesca Minoia (francesca.minoia@policlinico.mi.it)

Lead of science and research: Christoph Kessel (christoph.kessel@uni-muenster.de)

Lead of education and training: Sebastiaan Vastert (b.vastert@umcutrecht.nl)

PREs 2021 LIGHTENING TALKS & E-POSTERS on SJIA and MAS/sHLH

Lightening Talks

- MAS AND LUNG DISEASE AS COMPLICATIONS OF HLA-LINKED SEVERE DELAYED REACTIONS TO INHIBITORS OF IL-1 AND IL-6 IN STILL'S DISEASE – Vivian Saper, Stanford University
- MORTALITY AND CLINICAL RESPONSE TO TREATMENT IN CHILDREN WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (SHLH) – Claudia Bracaglia, Ospedale Pediatrico Bambino Gesù
- ACTIVATED CD8+ T CELLS DISCRIMINATES PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME FROM PATIENTS WITH ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – Giusi Prencipe, Ospedale Pediatrico Bambino Gesù
- DEVELOPMENT OF CLINICAL DEFINITIONS OF REFRACTORY DISEASE TRAJECTORIES IN SYSTEMIC JIA - Remco Erkens, UMC Utrecht
- NAIVE CD4+ T CELL DIFFERENTIATION IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IS SKEWED TOWARDS A PERIPHERAL T HELPER CELL PHENOTYPE - Julia KUEHN, Universitätsklinikum Münster
- SINGLE-CELL GENOMICS REVEALS A SHARED MONOCYTE INTERFERON PROGRAM IN A SUBSET OF PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS, MACROPHAGE ACTIVATION SYNDROME AND LUNG DISEASE - Emely Verweyen, Cincinnati Children Hospital Medical Center

E-Posters

- COMPARISON OF POTENTIAL BIOMARKERS DIFFERENTIATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS FROM OTHER CAUSES OF FEVER OF UNKNOWN ORIGIN IN CHILDREN – Pranav Chickermane, AMRITA INSTITUTE OF MEDICAL SCIENCES, KOCHI, INDIA
- EFFICACY OF EMAPALUMAB IN CHRONIC/RELAPSING MACROPHAGE ACTIVATION SYNDROME IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS WITH LUNG AND LIVER INVOLVEMENT – Alessia Arduini, Ospedale Pediatrico Bambino Gesù

MAS/sJIA Working Party

Chair: Claudia Bracaglia (claudia.bracaglia@opbg.net)

Secretary: Francesca Minoia (francesca.minoia@policlinico.mi.it)

Lead of science and research: Christoph Kessel (christoph.kessel@uni-muenster.de)

Lead of education and training: Sebastiaan Vastert (b.vastert@umcutrecht.nl)

- EXPERIENCE OF TOCILIZUMAB USE FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN UNDER 2 YEARS. – Ekaterina Alekseeva, NIIR BY NASONOVA
- FATTY ACID UPTAKE IS INCREASED IN MONOCYTES OF PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS AND BLOCKADE REGULATES IL8 AND TNFA PRODUCTION – Remco Erkens, UMC Utrecht
- LUNG FUNCTIONING AND INFLAMMATION IN A MOUSE MODEL OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – Bert Malangier Devlies, Rega Institute Ku Leuven
- NATURAL HISTORY OF DISEASE ON A SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS CASE WITHOUT DIAGNOSIS AND TREATMENT. A CASE REPORT IN A DEVELOPING COUNTRY. – Sandra Rodriguez Aguayio, HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ
- PERIPHERAL BLOOD GENE EXPRESSION ANALYSIS IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS AND MACROPHAGE ACTIVATION SYNDROME REVEALS DOMINANT INNATE IMMUNITY BUT NO INTERFERON-GAMMA SIGNATURE. – Claas Hinze, University Hospital Munster
- SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS ASSOCIATED LUNG DISEASE IN EUROPE – Claudia Bracaglia, Ospedale Pediatrico Bambino Gesù
- THALIDOMIDE IN 30 PATIENTS WITH REFRACTORY SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS – Archana Khan, NH SRCC Children Hospital, Mumbai
- WHAT IS HIDDEN UNDER THE DIAGNOSIS OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: LESSONS OF REAL CLINICAL PRACTICE – Svetlana Salugina, NIIR BY Nasonova
- RETROSPECTIVE ANALYSIS EVALUATING CLINICAL OUTCOMES IN TURKISH SJIA PATIENTS WITH BIOLOGICAL THERAPEUTIC AGENTS - TURSIS STUDY – Betül Sozeri, UMRANIYE EDUCATION AND RESEARCH HOSPITAL
- APPLICABILITY OF THE HSCORE CRITERIA IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME - Marina Idalia De La Cera Rodríguez, HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ
- CENTRAL NERVOUS SYSTEM INVOLVEMENT AS A PREDICTOR OF EARLY DEATH IN CHILDREN WITH MACROPHAGE ACTIVATION SYNDROME AND INFECTION-ASSOCIATED HEMOPHAGOCYTIC SYNDROME - Saralee Harnchoowong, RAMATHIBODI HOSPITAL, MAHIDOL UNIVERSITY

MAS/sJIA Working Party

Chair: Claudia Bracaglia (claudia.bracaglia@opbg.net)

Secretary: Francesca Minoia (francesca.minoia@policlinico.mi.it)

Lead of science and research: Christoph Kessel (christoph.kessel@uni-muenster.de)

Lead of education and training: Sebastiaan Vastert (b.vastert@umcutrecht.nl)

- TRADITIONAL LABORATORY PARAMETERS AND NEW BIOMARKERS IN MACROPHAGE ACTIVATION SYNDROME (MAS) AND SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (SHLH) – Arianna De Matteis, Ospedale Pediatrico Bambino Gesù
- PRIMARY AND SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH) IN PEDIATRIC INTENSIVE CARE: CLINICAL CHARACTERISTICS, THERAPIES AND OUTCOMES – Manuel Murciano, Ospedale Pediatrico Bambino Gesù
- LYSINURIC PROTEIN INTOLERANCE MIMICKING LUPUS PRESENTING AS MACROPHAGE ACTIVATION SYNDROME - Belde Kasap Demir - TEPECIK TRAINING AND RESEARCH HOSPITAL
- AN UNUSUAL CASE OF SYSTEMIC LUPUS ERYTHEMATOSUS WITH SJÖGREN SYNDROME AND RECURRING EPISODES OF MACROPHAGE ACTIVATION SYNDROME IN A BOY – DIFFICULTIES TO DIAGNOSE, DIFFICULTIES TO TREAT. – Irina Nikishina, NIIR BY Nasonova
- WHEN MACROPHAGE ACTIVATION SYNDROME PRESENTS AT DIAGNOSIS – Mafalda Pereira, ALGARVE UNIVERSITY HOSPITAL CENTER – FARO'S HOSPITAL